Skip to main content
. 2025 Jun 10;167(1):166. doi: 10.1007/s00701-025-06587-4

Table 3.

Trials assessing MMAE as adjunct to surgery (N = 16)

Trial Name Country Size End date Status Population Industry funded Agent Primary outcome Follow-up
DAMMET USA 40 01–24 Completed None No Not stated Repeat surgery 3 months
STORMM Switzerland 180 01–27 Not yet recruiting Symptoms or failed conservative No Not stated Symptomatic recurrence, repeat surgery, or on scan 6 months
OTEMACS France 440 12–22 Unknown Symptoms + MRS 3 or less No Onyx™ Repeat surgery or radiological 3 months
MEMBRANE Germany 376 05–25 Active, not recruiting MRS 3 or less Yes TRUFIILL n-BCA® (Cyanoacrilates) Resolution 6 months
LEADH France 550 09–26 Recruiting None No Cyanoacrilates Repeat surgery or radiological 6 months
ChiCTR2000039359 China 480 11–21 Not yet recruiting “Requiring surgery” No Not stated Repeat surgery or radiological Not stated
METRICS China 546 12–24 Not yet recruiting One risk factor for recurrence No Not stated Repeat surgery or radiological or new disability from neurological cause 6 months
NCT04065113 USA 600 01–25 Unknown Symptoms No PVA particles Repeat surgery 3 months
ELIMINATE Netherlands 170 10–25 Recruiting Symptoms No PVA particles Repeat surgery 6 Months
EMMA-Can 1 Canada 200 01–26 Recruiting Symptoms and MRS 2 or less No PVA particles Radiological 3 Months
MEMBRANE Germany 154 10–25 Recruiting None No PVA particles or Onyx™ Repeat surgery or radiological 3 Months
ENCLOSURE Spain 280 12–23 Unknown  > 10 mm or symptoms No Onyx™, SQUID®, Phil™, Libro® Radiological 6 Months
EMPROTECT France 342 12–22 Unknown Recurrence or high risk of No Not stated Repeat surgery or radiological 6 Months
ChiCTR1800018714 China 60 12–20 Recruiting Symptoms No Not stated Repeat surgery Not stated
NCT04272996 USA 60 06–24 Recruiting Symptoms and MRS 4 or less No Not stated Radiological 3 Months
U1111-1254–3825 Australia 72 04–24 Recruiting Symptoms Yes Not stated Radiological and new symptoms requiring surgery 6 Months